Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KM871 monoclonal antibody

Known as: KM871, mAb KM871, monoclonal antibody KM871 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
We conducted an open label dose-escalation phase I trial of chimeric anti-GD3 mAb KM871 in patients with metastatic melanoma… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2005
2005
Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface of human tumors of neuroectodermal origin… Expand
  • figure 2
  • figure 6
  • figure 4
  • figure 7
  • figure 5
Is this relevant?
2002
2002
The chimeric KM871 monoclonal antibody targets the GD3 disialoganglioside antigen and is under investigation for its… Expand
Is this relevant?
2002
2002
The chimeric KM871 monoclonal antibody targets the GD3 disialoganglioside antigen and is under investigation for its… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2001
2001
PURPOSE KM871 is a chimeric monoclonal antibody against the ganglioside antigen GD3, which is highly expressed on melanoma cells… Expand
Is this relevant?
2001
2001
The chimeric monoclonal antibody KM871, directed against the G(D3) antigen, is under evaluation for its potential to target… Expand
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
2000
2000
Abstract KM871 is a chimeric antibody recognizing ganglioside GD3, which is one of the major gangliosides expressed on the cell… Expand
  • table 2
  • figure 1
  • table 1
  • figure 2
  • table 4
Is this relevant?
2000
2000
Abstract Several gangliosides such as GM2, GD2, and GD3 have been thought of as target molecules for active or passive… Expand
Is this relevant?